allyloxynaphthalenone | 88628-51-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: allyloxynaphthalenone
• 英文别名: 6-allyloxy-tetral-1-one；6-allyloxytetralone；6-allyloxy-1-tetralone；6-(allyloxy)-3,4-dihydronaphthalen-1(2H)-one；6-(2-propenyloxy)-1,2,3,4-tetrahydronaphthalen-1-one；3,4-dihydro-6-(2-propenyloxy)-1(2H)-naphthalenone；6-Prop-2-enyloxy-2,3,4-trihydronaphthalen-1-one；6-allyloxy-1,2,3,4-tetrahydro-1-naphthalenone；1(2H)-Naphthalenone, 3,4-dihydro-6-(2-propenyloxy)-；6-prop-2-enoxy-3,4-dihydro-2H-naphthalen-1-one
• CAS: 88628-51-7
• 化学式: C₁₃H₁₄O₂
• 分子量: 202.253
• InChiKey: LWANBOPSQQCDSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  allyloxynaphthalenone 在 sodium sulfide 、 四(三苯基膦)钯 、 草酰氯 、 potassium tert-butylate 、 氧气 、 potassium carbonate 、 caesium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 叔丁醇 为溶剂， 反应 179.25h， 生成 2-hydroxydinaphtho[2,3-b:2',3'-d]thiophene-5,7,12,13-tetraone
  参考文献：
  名称：

  丝氨酸醌类似物作为黑色素瘤药物的研究进展。

  摘要：

  Seriniquinone是一种海洋天然产物，对黑素瘤癌细胞显示出强大的细胞毒性和选择性。这种选择性与新颖的作用模式（MOA）相结合，促使人们进行研究以翻译出与药理相关的药物。本文中，我们报道了结构活性关系（SARs），并提供了制备保留活性并提供改善的水溶性和异构体纯度的类似物的策略。由以克为单位的中间体制备衍生物，并评估其抗增殖活性和黑色素瘤选择性。总的来说，这些研究提供了安装侧链基序的方法，这些基序显示出共同但独特的生物学特征。

  DOI：

  10.1021/acsmedchemlett.8b00391
• 作为产物：
  描述：

  6-甲氧基-1-萘满酮 在 氢溴酸 作用下， 反应 36.0h， 生成 allyloxynaphthalenone
  参考文献：
  名称：

  尼康酮的对映选择性全合成

  摘要：

  d p-TsOH，MeOH，23°C。e LDA, TMSCl, -78 °C。f Pd(OAc)2 ,O 2, DMSO, 23 °C。g L-selectride，THF，-78 °C。h t-BuOOH, VO(acac)2 ,CH 2Cl2 ,0 °C。i Ac2O、Et3N、DMAP，-25 °C。n K 2CO3，甲醇，23 °C。o MgI2、NaI、CH2Cl2-CH3CN，0 °C。p CH3SO2Cl, Et3N,

  DOI：

  10.1021/ja0024892

文献信息

• Indole derivative having piperidine ring
  申请人：Suzuki Yuichi

  公开号：US20050256103A1

  公开（公告）日：2005-11-17

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

  本发明涉及以下公式所代表的化合物，其药学上可接受的盐，或其作为药物的用途： 其中R1和R2是相邻的取代基，与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物，该基可能被1至4个取代基所取代，所述取代基选自（1）氧代基，（2）羟基等；R3代表氢原子或类似物；R6代表氢原子或类似物。 本发明的目的是发现一种用于治疗或预防下尿道症状，特别是涉及尿液储存的症状的药剂，该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。
• 5- substituted tetralones as inhibitors of ras farnesyl trransferase
  申请人：——

  公开号：US20040044057A1

  公开（公告）日：2004-03-04

  The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme. 1

  本发明提供了式(I)、(II)、(III)和(IV)的新型5-取代四酮及其药学上可接受的盐、酯、酰胺和前药，用于治疗和预防组织的不受控制或异常增殖，如癌症、动脉粥样硬化、再狭窄和银屑病。具体而言，本发明涉及抑制法尼基转移酶酶的化合物。
• Synthesis of 2-(N-substituted amino)-6-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol derivatives.
  作者：AKIO MIYAKE、KATSUMI ITOH、NORIO TADA、MASAO TANABE、MINORU HIRATA、YOSHIKAZU OKA

  DOI：10.1248/cpb.31.2329

  日期：——

  trans-6-Hydroxy-2-(1-methyl-3-phenylpropyl) amino-1, 2, 3, 4-tetrahydronaphthalen-1-ol (8a), trans-6-hydroxy-2-(1-methyl-2-phenoxyethyl) amino-1, 2, 3, 4-tetrahydronaphthalen-1-ol (8b) and trans-1, 6-dihydroxy-2-(1-methyl-3-phenylpropyl) amino-1, 2, 3, 4-tetrahydronaphthalene-5-carboxamide (9a) were synthesized as a part of our search for useful cardiovascular agents. 2-(N-Substituted amino)-6-alkoxy-1, 2, 3, 4-tetrahydronaphthalen-1-ols (10-31) having various substituents at the 5-, 6- and 7-positions of the naphthalene ring were prepared by a five-step sequence of reactions starting from 3, 4-dihydro-1 (2H)-naphthalenone derivatives (36). Furthermore 2-(N-substituted amino)-1-indanol derivatives (33) and 6-(N-substituted amino)-2-hydroxy-6, 7, 8, 9-tetrahydro-5H-benzocyclohepten-5-ols (34, 35) were obtained by the reductive alkylation of the corresponding amino alcohols with carbonyl compounds. These N-substituted amino alcohols (8-35) were tested for vasodilating activity in anesthetized dogs and for β-blocking activity using isolated guinea pig atrial preparations.

  trans-6-羟基-2-(1-甲基-3-苯基丙基)氨基-1,2,3,4-四氢萘-1-醇(8a)、trans-6-羟基-2-(1-甲基-2-苯氧乙基)氨基-1,2,3,4-四氢萘-1-醇(8b)和trans-1,6-二羟基-2-(1-甲基-3-苯基丙基)氨基-1,2,3,4-四氢萘-5-羧酰胺(9a)作为我们寻找有用的心血管药物的一部分被合成。通过从3,4-二氢-1(2H)-萘满酮衍生物(36)开始，经过五步反应序列，制备了在萘环的5-、6-和7-位具有各种取代基的2-(N-取代氨基)-6-烷氧基-1,2,3,4-四氢萘-1-醇(10-31)。此外，2-(N-取代氨基)-1-茚醇衍生物(33)和6-(N-取代氨基)-2-羟基-6,7,8,9-四氢-5H-苯并环庚烯-5-醇(34,35)是通过相应的氨基醇与羰基化合物的还原烷基化获得的。这些N-取代的氨基醇(8-35)在麻醉犬中测试了其血管舒张活性，并在离体的豚鼠心房制备中测试了其β-阻断活性。
• Aminoalkyl dihydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US04473586A1

  公开（公告）日：1984-09-25

  Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.10 are independently selected from hydrogen, hydroxy, methoxy, loweralkyl of 1 to 4 carbon atoms, or halo, or R.sub.9 and R.sub.10 can be taken together to form a methylenedioxy or ethylenedioxy bridge; or 1,4-benzodioxan of the formula ##STR5## wherein q is 1, 2 or 3, and R.sub.11 is hydrogen, methoxy, or halo; or R.sub.3 and R.sub.4 can be taken together to form a piperazino, piperidino or morpholino moiety; and the pharmaceutically acceptable salts thereof. Also disclosed are novel intermediates useful in the preparation of these compounds.

  本公开涉及由下式表示的1-氨基烷基-3,4-二氢萘烯衍生物，其中n为1或2；R、R.sub.1和R.sub.2分别选自氢、羟基、1至3个碳原子的低烷氧基、1至3个碳原子的低烯氧基、硫甲基、卤素，或下式中的其中一种：其中R.sub.5和R.sub.6分别选自氢、1至4个碳原子的低酰基或下式的磺酰基：其中R.sub.7为1至4个碳原子的低烷基；或R和R.sub.1，或R.sub.1和R.sub.2可结合形成亚甲二氧桥或乙烯二氧桥；但R、R.sub.1或R.sub.2中至少有一个必须为氢以外的其他基团；R.sub.3和R.sub.4分别选自氢、1至4个碳原子的低烷基、1至4个碳原子的卤素取代的低烷基、下式的芳基烷基：其中m为0、1或2，p为0或1，R.sub.8为氢或1至4个碳原子的低烷基，R.sub.9和R.sub.10分别选自氢、羟基、甲氧基、1至4个碳原子的低烷基或卤素，或R.sub.9和R.sub.10可结合形成亚甲二氧桥或乙烯二氧桥；或下式的1,4-苯二氧杂环己烷：其中q为1、2或3，R.sub.11为氢、甲氧基或卤素；或R.sub.3和R.sub.4可结合形成哌嗪基、哌啶基或吗啉基；以及其药用盐。还公开了用于制备这些化合物的新型中间体。
• Carboxylic acid Leukotriene B4 antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US05457124A1

  公开（公告）日：1995-10-10

  The invention relates to compounds selected from the group consisting of the formulas: ##STR1## wherein R.sup.2 and Ph are as described herein. These compounds are potent leukotriene B.sub.4 antagonists and are therefore useful in the treatment of inflammatory diseases.

  这项发明涉及从以下公式组成的化合物中选择的化合物：##STR1## 其中R.sup.2和Ph如本文所述。 这些化合物是强效的白三烯B.sub.4拮抗剂，因此在治疗炎症性疾病方面非常有用。